x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Delaware
(State
or Other Jurisdiction of Incorporation or Organization)
|
75-3142681
(I.R.S.
Employer Identification No.)
|
811
Hansen Way, Palo Alto, California 94303
(Address
of Principal Executive Offices and Zip Code)
|
|
(650)
846-2900
(Registrant’s
telephone number, including area code)
|
|
Not
Applicable
(Former
name, former address and former fiscal year, if changed since last
report)
|
4
|
||||
4
|
||||
4
|
||||
5
|
||||
6
|
||||
7
|
||||
39
|
||||
62
|
||||
64
|
||||
65
|
||||
65
|
||||
65
|
||||
65
|
||||
65
|
||||
65
|
||||
65
|
||||
66
|
|
June
27,
|
September
28,
|
||||||
2008
|
2007
|
|||||||
Assets
|
||||||||
Current
Assets:
|
||||||||
Cash
and cash equivalents
|
$ | 26,197 | $ | 20,474 | ||||
Restricted
cash
|
1,205 | 2,255 | ||||||
Accounts
receivable, net
|
48,379 | 52,589 | ||||||
Inventories
|
67,868 | 67,447 | ||||||
Deferred
tax assets
|
10,023 | 9,744 | ||||||
Prepaid
and other current assets
|
5,057 | 4,639 | ||||||
Total
current assets
|
158,729 | 157,148 | ||||||
Property,
plant, and equipment, net
|
63,487 | 66,048 | ||||||
Deferred
debt issue costs, net
|
5,362 | 6,533 | ||||||
Intangible
assets, net
|
79,355 | 81,743 | ||||||
Goodwill
|
162,392 | 161,573 | ||||||
Other
long-term assets
|
795 | 3,177 | ||||||
Total
assets
|
$ | 470,120 | $ | 476,222 | ||||
Liabilities
and stockholders’ equity
|
||||||||
Current
Liabilities:
|
||||||||
Current
portion of long-term debt
|
$ | 2,000 | $ | 1,000 | ||||
Accounts
payable
|
21,950 | 21,794 | ||||||
Accrued
expenses
|
26,373 | 26,349 | ||||||
Product
warranty
|
4,533 | 5,578 | ||||||
Income
taxes payable
|
7,594 | 8,748 | ||||||
Advance
payments from customers
|
12,184 | 12,132 | ||||||
Total
current liabilities
|
74,634 | 75,601 | ||||||
Deferred
income taxes
|
26,760 | 28,394 | ||||||
Long-term
debt, less current portion
|
228,642 | 245,567 | ||||||
Other
long-term liabilities
|
1,199 | 754 | ||||||
Total
liabilities
|
331,235 | 350,316 | ||||||
Commitments
and contingencies
|
||||||||
Stockholders’
equity
|
||||||||
Common
stock ($0.01 par value, 90,000 shares authorized;
16,511 and 16,370 shares issued; 16,375
and 16,370 shares outstanding)
|
165
|
164 | ||||||
Additional
paid-in capital
|
70,987 | 68,763 | ||||||
Accumulated
other comprehensive (loss) income
|
(997 | ) | 937 | |||||
Retained
earnings
|
70,530 | 56,042 | ||||||
Treasury
stock, at cost (136 and 0 shares)
|
(1,800 | ) | - | |||||
Total
stockholders’ equity
|
138,885 | 125,906 | ||||||
Total
liabilities and stockholders' equity
|
$ | 470,120 | $ | 476,222 |
Three Months Ended
|
Nine
Months Ended
|
|||||||||||||||
June 27,
2008
|
June 29,
2007
|
June 27,
2008
|
June 29,
2007
|
|||||||||||||
Sales
|
$ | 90,734 | $ | 87,318 | $ | 271,448 | $ | 259,485 | ||||||||
Cost
of sales
|
63,502 | 58,667 | 192,014 | 176,548 | ||||||||||||
Gross
profit
|
27,232 | 28,651 | 79,434 | 82,937 | ||||||||||||
Operating
costs and expenses:
|
||||||||||||||||
Research
and development
|
2,766 | 2,232 | 8,420 | 6,475 | ||||||||||||
Selling
and marketing
|
5,012 | 4,911 | 15,512 | 14,539 | ||||||||||||
General
and administrative
|
5,136 | 5,835 | 16,781 | 16,085 | ||||||||||||
Amortization
of acquisition-related intangible assets
|
782 | 548 | 2,344 | 1,642 | ||||||||||||
Net
loss on disposition of fixed assets
|
128 | 16 | 203 | 74 | ||||||||||||
Total
operating costs and expenses
|
13,824 | 13,542 | 43,260 | 38,815 | ||||||||||||
Operating
income
|
13,408 | 15,109 | 36,174 | 44,122 | ||||||||||||
Interest
expense, net
|
4,627 | 5,143 | 14,244 | 15,757 | ||||||||||||
Loss
on debt extinguishment
|
121 | - | 514 | - | ||||||||||||
Income
before income taxes
|
8,660 | 9,966 | 21,416 | 28,365 | ||||||||||||
Income
tax expense
|
2,836 | 1,835 | 6,928 | 8,639 | ||||||||||||
Net
income
|
$ | 5,824 | $ | 8,131 | $ | 14,488 | $ | 19,726 | ||||||||
Other
comprehensive income, net of tax
|
||||||||||||||||
Net
unrealized gain (loss) on cash flow hedges
|
1,268 | 820 | (1,934 | ) | 414 | |||||||||||
Comprehensive
income
|
$ | 7,092 | $ | 8,951 | $ | 12,554 | $ | 20,140 | ||||||||
Earnings
per share - Basic
|
$ | 0.36 | $ | 0.50 | $ | 0.88 | $ | 1.22 | ||||||||
Earnings
per share - Diluted
|
$ | 0.33 | $ | 0.46 | $ | 0.82 | $ | 1.11 | ||||||||
Shares
used to compute earnings per share - Basic
|
16,395 | 16,306 | 16,384 | 16,207 | ||||||||||||
Shares
used to compute earnings per share - Diluted
|
17,669 | 17,796 | 17,719 | 17,696 |
Nine Months Ended
|
||||||||||
June
27,
|
June
29,
|
|||||||||
2008
|
2007
|
|||||||||
Cash
flows from operating activities
|
||||||||||
Net
cash provided by operating activities
|
$ |
24,699
|
$ |
19,259
|
||||||
Cash
flows from investing activities
|
||||||||||
Capital
expenditures
|
(3,288)
|
(6,392)
|
||||||||
Proceeds
from adjustment to acquisition purchase price
|
1,615
|
-
|
||||||||
Capitalized
expenses relating to potential business acquisition
|
-
|
(395)
|
||||||||
Payment
of patent application fees
|
(147)
|
-
|
||||||||
Net
cash used in investing activities
|
(1,820)
|
(6,787)
|
||||||||
Cash
flows from financing activities
|
||||||||||
Purchases
of treasury stock
|
(1,800)
|
-
|
||||||||
Repayments
of debt
|
(16,000)
|
(5,000)
|
||||||||
Proceeds
from issuance of common stock to employees
|
639
|
520
|
||||||||
Proceeds
from exercise of stock options
|
3
|
604
|
||||||||
Excess
tax benefit on stock option exercises
|
2
|
671
|
||||||||
Net
cash used in financing activities
|
(17,156)
|
(3,205)
|
||||||||
Net
increase in cash and cash equivalents
|
5,723
|
9,267
|
||||||||
Cash
and cash equivalents at beginning of period
|
20,474
|
30,153
|
||||||||
Cash
and cash equivalents at end of period
|
$ |
26,197
|
$ |
39,420
|
||||||
Supplemental
cash flow disclosures
|
||||||||||
Cash
paid for interest
|
$ |
10,020
|
$ |
11,562
|
||||||
Cash
paid for income taxes, net of refunds
|
$ |
9,846
|
$ |
12,799
|
1.
|
The
Company and a Summary of its Significant Accounting
Policies
|
2.
|
Recently
Issued Accounting Standards
|
3. | Supplemental Balance Sheet Information |
June
27,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
Accounts
receivable
|
$ | 48,477 | $ | 52,678 | ||||
Less:
Allowance for doubtful accounts
|
(98 | ) | (89 | ) | ||||
Accounts
receivable, net
|
$ | 48,379 | $ | 52,589 |
June
27,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
Raw
material and parts
|
$ | 39,168 | $ | 40,725 | ||||
Work
in process
|
20,899 | 18,168 | ||||||
Finished
goods
|
7,801 | 8,554 | ||||||
$ | 67,868 | $ | 67,447 |
Nine Months Ended
|
||||||||
June
27,
|
June
29,
|
|||||||
2008
|
2007
|
|||||||
Balance
at beginning of fiscal year
|
$ | 9,784 | $ | 8,822 | ||||
Inventory
provision, charged to cost of sales
|
988 | 803 | ||||||
Inventory
write-offs
|
(1,619 | ) | (710 | ) | ||||
Balance
at end of period
|
$ | 9,153 | $ | 8,915 |
Nine Months Ended
|
||||||||
June
27,
|
June
29,
|
|||||||
2008
|
2007
|
|||||||
Balance
at beginning of fiscal year
|
$ | 2,700 | $ | 1,702 | ||||
Provision
for loss contracts, charged to cost of sales
|
1,932 | 970 | ||||||
Reduction
upon revenue recognition
|
(2,702 | ) | (1,202 | ) | ||||
Balance
at end of period
|
$ | 1,930 | $ | 1,470 |
June
27,
|
June
29,
|
|||||||
2008
|
2007
|
|||||||
Inventories
|
$ | 1,112 | $ | 1,294 | ||||
Accrued
expenses
|
818 | 176 | ||||||
$ | 1,930 | $ | 1,470 |
Weighted Average Useful Life
(in years)
|
June 27, 2008
|
September 28, 2007
|
||||||||||||||||||||||||||
Cost
|
Accumulated Amortization
|
Net
|
Cost
|
Accumulated Amortization
|
Net
|
|||||||||||||||||||||||
VED
Core Technology
|
50
|
$ | 30,700 | $ | (2,734 | ) | $ | 27,966 | $ | 30,700 | $ | (2,273 | ) | $ | 28,427 | |||||||||||||
VED
Application Technology
|
25
|
19,800 | (3,515 | ) | 16,285 | 19,800 | (2,921 | ) | 16,879 | |||||||||||||||||||
X-ray
Generator and Satcom
|
||||||||||||||||||||||||||||
Application Technology
|
15
|
8,000 | (2,374 | ) | 5,626 | 8,000 | (1,974 | ) | 6,026 | |||||||||||||||||||
Antenna
and Telemetry
|
||||||||||||||||||||||||||||
Technology
|
25
|
5,300 | (188 | ) | 5,112 | 5,300 | (29 | ) | 5,271 | |||||||||||||||||||
Customer
backlog
|
1
|
580 | (513 | ) | 67 | 580 | (78 | ) | 502 | |||||||||||||||||||
Land
lease
|
46
|
11,810 | (1,118 | ) | 10,692 | 11,810 | (928 | ) | 10,882 | |||||||||||||||||||
Tradename
|
Indefinite
|
7,600 | - | 7,600 | 7,600 | - | 7,600 | |||||||||||||||||||||
Customer
list and programs
|
25
|
6,280 | (884 | ) | 5,396 | 6,280 | (684 | ) | 5,596 | |||||||||||||||||||
Noncompete
agreement
|
5
|
640 | (176 | ) | 464 | 640 | (80 | ) | 560 | |||||||||||||||||||
Patent
application fees
|
-
|
147 | - | 147 | - | - | - | |||||||||||||||||||||
$ | 90,857 | $ | (11,502 | ) | $ | 79,355 | $ | 90,710 | $ | (8,967 | ) | $ | 81,743 |
Fiscal Year
|
Amount
|
|||
2008
(remaining three months)
|
$ | 769 | ||
2009
|
2,808 | |||
2010
|
2,786 | |||
2011
|
2,786 | |||
2012
|
2,772 | |||
Thereafter
|
59,834 | |||
$ | 71,755 |
VED
|
Satcom
|
Other
|
Total
|
|||||||||||||
Balance
at September 28, 2007
|
$ | 132,897 | $ | 13,830 | $ | 14,846 | $ | 161,573 | ||||||||
Malibu
purchase price and allocation adjustment
|
- | - | 925 | 925 | ||||||||||||
Other
adjustments
|
- | - | (106 | ) | (106 | ) | ||||||||||
Balance
at June 27, 2008
|
$ | 132,897 | $ | 13,830 | $ | 15,665 | $ | 162,392 |
Nine Months Ended
|
||||||||
June
27,
|
June
29,
|
|||||||
2008
|
2007
|
|||||||
Balance
at beginning of fiscal year
|
$ | 5,578 | $ | 5,958 | ||||
Estimates
for product warranty, charged to cost of sales
|
2,171 | 3,801 | ||||||
Actual
costs of warranty claims
|
(3,216 | ) | (4,232 | ) | ||||
Balance
at end of period
|
$ | 4,533 | $ | 5,527 |
4.
|
Acquisition
|
Net
current liabilities
|
$ | (3,854 | ) | |
Property,
plant and equipment
|
719 | |||
Deferred
tax liabilities
|
(703 | ) | ||
Identifiable
intangible assets
|
8,790 | |||
Goodwill
|
15,781 | |||
$ | 20,733 |
Weighted Average Useful Life
(in years)
|
Amount
|
|||||||
Non
compete agreements
|
5
|
$ | 530 | |||||
Tradename
|
Indefinite
|
1,800 | ||||||
Antenna
and Telemetry technology
|
25
|
5,300 | ||||||
Backlog
|
1
|
580 | ||||||
Customer
relationships
|
15
|
580 | ||||||
$ | 8,790 |
5. | Long-Term Debt |
June
27,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
Term
loan, expiring 2014
|
$ | 91,750 | $ | 99,750 | ||||
8%
Senior subordinated notes due 2012
|
125,000 | 125,000 | ||||||
Floating
rate senior notes due 2015, net of issue discount of $108 and
$183
|
13,892 | 21,817 | ||||||
230,642 | 246,567 | |||||||
Less: Current
portion
|
2,000 | 1,000 | ||||||
Long-term
portion
|
$ | 228,642 | $ | 245,567 | ||||
Standby
letters of credit
|
$ | 4,986 | $ | 3,725 |
Year
|
Optional
Redemption Price
|
|||
2008
|
104 | % | ||
2009
|
102 | % | ||
2010
and thereafter
|
100 | % |
Year
|
Optional
Redemption Price
|
|||
2007
|
103 | % | ||
2008
|
102 | % | ||
2009
|
101 | % | ||
2010
and thereafter
|
100 | % |
Fiscal Year
|
Term
Loan
|
8% Senior
Subordinated Notes
|
Floating Rate
Senior Notes
|
Total
|
||||||||||||
2008
(remaining three months)
|
$ | 2,000 | $ | - | $ | - | $ | 2,000 | ||||||||
2009
|
- | - | - | - | ||||||||||||
2010
|
- | - | - | - | ||||||||||||
2011
|
89,750 | - | - | 89,750 | ||||||||||||
2012
|
- | 125,000 | - | 125,000 | ||||||||||||
Thereafter
|
- | - | 14,000 | 14,000 | ||||||||||||
$ | 91,750 | $ | 125,000 | $ | 14,000 | $ | 230,750 |
Fiscal
Year
|
Operating
Leases
|
|||
2008
(remaining three months)
|
$ | 573 | ||
2009
|
1,966 | |||
2010
|
1,657 | |||
2011
|
552 | |||
2012
|
456 | |||
Thereafter
|
3,094 | |||
|
$ | 8,298 |
Fiscal
Year
|
Purchase
Contracts
|
|||
2008
(remaining three months)
|
$ | 24,328 | ||
2009
|
11,939 | |||
2010
|
1,350 | |||
2011
|
419 | |||
|
$ | 38,036 |
8.
|
Stock
Repurchase Program
|
9.
|
Stock-based
Compensation Plans
|
Oustanding Options
|
Exercisable Options
|
|||||||||||||||||||||||||||||||
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
|||||||||||||||||||||||||
Balance
at September 28, 2007
|
3,171,081 | $ | 5.61 | 6.58 | $ | 42,513 | 2,259,528 | $ | 3.00 | 5.98 | $ | 36,184 | ||||||||||||||||||||
Granted
|
208,750 | 16.79 | ||||||||||||||||||||||||||||||
Exercised
|
(599 | ) | 4.32 | |||||||||||||||||||||||||||||
Forfeited
or cancelled
|
(4,400 | ) | 16.58 | |||||||||||||||||||||||||||||
Balance
at June 27, 2008
|
3,374,832 | $ | 6.29 | 6.04 | $ | 25,131 | 2,565,069 | $ | 3.83 | 5.41 | $ | 23,774 |
Number
of Shares
|
Weighted-Average
Grant-Date Fair Value
|
|||||||
Nonvested
at September 28, 2007
|
11,466 | $ | 17.44 | |||||
Granted
|
114,461 | 15.22 | ||||||
Vested
|
(5,848 | ) | 17.60 | |||||
Forfeited
|
(525 | ) | 16.79 | |||||
Nonvested
at June 27, 2008
|
119,554 | $ | 15.31 |
Three Months Ended
|
Nine Months Ended
|
||||||||||||||||
June 27,
2008
|
June 29,
2007
|
June 27,
2008
|
June 29,
2007
|
||||||||||||||
Share-based
compensation cost recognized in the income statement by
caption:
|
|||||||||||||||||
Cost
of sales
|
$ | 116 | $ | 75 | $ | 307 | $ | 196 | |||||||||
Research
and development
|
43 | 25 | 112 | 68 | |||||||||||||
Selling
and marketing
|
61 | 28 | 165 | 87 | |||||||||||||
General
and administrative
|
374 | 209 | 984 | 538 | |||||||||||||
$ | 594 | $ | 337 | $ | 1,568 | $ | 889 | ||||||||||
Share-based
compensation cost capitalized in inventory
|
$ | 120 | $ | 78 | $ | 335 | $ | 206 | |||||||||
Share-based
compensation cost remaining in inventory at end of period
|
$ | 74 | $ | 39 | $ | 74 | $ | 39 | |||||||||
Share-based
compensation expense by type of award:
|
|||||||||||||||||
Stock
options
|
$ | 421 | $ | 277 | $ | 1,153 | $ | 712 | |||||||||
Restricted
stock and restricted stock units
|
134 | 27 | 301 | 85 | |||||||||||||
Stock
purchase plan
|
39 | 33 | 114 | 92 | |||||||||||||
$ | 594 | $ | 337 | $ | 1,568 | $ | 889 |
Three
Months Ended
|
Nine
months ended
|
||||||||||||||||
June
27,
2008
|
June
29,
2007
|
June
27,
2008
|
June
29,
2007
|
||||||||||||||
Expected
term (in years)
|
*
|
6.25 | 6.25 | 6.00 – 6.25 | |||||||||||||
Expected
volatility
|
*
|
49.33 | % | 41.20 | % | 49.33 | % | ||||||||||
Risk-free
rate
|
*
|
4.69 | % | 3.82 | % | 4.56% – 4.71 | % | ||||||||||
Dividend yield |
|
*
|
0 | % | 0 | % | 0 | % | |||||||||
*
No new stock options were granted during the three months ended June 27,
2008.
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
June 27,
2008
|
June 29,
2007
|
June 27,
2008
|
June 29,
2007
|
|||||||||||||
Weighted
average common shares outstanding -- Basic
|
16,395 | 16,306 | 16,384 | 16,207 | ||||||||||||
Effect
of dilutive stock options and nonvested restricted stock awards and
units
|
1,274 | 1,490 | 1,335 | 1,489 | ||||||||||||
Weighted
average common shares outstanding -- Diluted
|
17,669 | 17,796 | 17,719 | 17,696 |
Three
Months Ended
|
Nine
Months Ended
|
||||||||||||||||
June
27,
|
June
29,
|
June
27,
|
June
29,
|
||||||||||||||
2008
|
2007
|
2008
|
2007
|
||||||||||||||
Sales
to external customers
|
|||||||||||||||||
VED
|
$ | 68,770 | $ | 70,651 | $ | 206,504 | $ | 209,842 | |||||||||
Satcom
equipment
|
18,550 | 16,667 | 53,259 | 49,643 | |||||||||||||
Other
|
3,414 | - | 11,685 | - | |||||||||||||
$ | 90,734 | $ | 87,318 | $ | 271,448 | $ | 259,485 | ||||||||||
Intersegment
product transfers
|
|||||||||||||||||
VED
|
$ | 7,799 | $ | 6,903 | $ | 20,947 | $ | 16,608 | |||||||||
Satcom
equipment
|
9 | 1 | 72 | 10 | |||||||||||||
$ | 7,808 | $ | 6,904 | $ | 21,019 | $ | 16,618 | ||||||||||
Capital
expenditures
|
|||||||||||||||||
VED
|
$ | 529 | $ | 1,009 | $ | 1,873 | $ | 6,240 | |||||||||
Satcom
equipment
|
- | 13 | 654 | 35 | |||||||||||||
Other
|
201 | 24 | 761 | 117 | |||||||||||||
$ | 730 | $ | 1,046 | $ | 3,288 | $ | 6,392 | ||||||||||
EBITDA
|
|||||||||||||||||
VED
|
$ | 17,548 | $ | 19,231 | $ | 49,835 | $ | 54,747 | |||||||||
Satcom
equipment
|
1,332 | 1,842 | 3,709 | 4,460 | |||||||||||||
Other
|
(2,814 | ) | (3,739 | ) | (9,713 | ) | (8,478 | ) | |||||||||
$ | 16,066 | $ | 17,334 | $ | 43,831 | $ | 50,729 |
June
27,
|
September
28,
|
||||||||
2008
|
2007
|
||||||||
Total
assets
|
|||||||||
VED
|
$ | 326,311 | $ | 335,926 | |||||
Satcom
equipment
|
49,583 | 49,266 | |||||||
Other
|
92,712 | 91,030 | |||||||
$ | 468,606 | $ | 476,222 |
|
•
|
EBITDA
is a component of the measures used by the Company’s board of directors
and management team to evaluate the Company’s operating
performance;
|
|
•
|
the
Senior Credit Facilities contain a covenant that requires the Company to
maintain a senior secured leverage ratio that contains EBITDA as a
component, and the Company’s management team uses EBITDA to monitor
compliance with this covenant;
|
|
•
|
EBITDA
is a component of the measures used by the Company’s management team to
make day-to-day operating
decisions;
|
|
•
|
EBITDA
facilitates comparisons between the Company’s operating results and those
of competitors with different capital structures and therefore is a
component of the measures used by the Company’s management to facilitate
internal comparisons to competitors’ results and the Company’s industry in
general; and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by the Company of certain targets that contain EBITDA as a
component.
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||||
June 27,
2008
|
June 29,
2007
|
June 27,
2008
|
June 29,
2007
|
||||||||||||||
Net
income
|
$ | 5,824 | $ | 8,131 | $ | 14,488 | $ | 19,726 | |||||||||
Depreciation
and amortization
|
2,779 | 2,225 | 8,171 | 6,607 | |||||||||||||
Interest
expense, net
|
4,627 | 5,143 | 14,244 | 15,757 | |||||||||||||
Income
tax expense
|
2,836 | 1,835 | 6,928 | 8,639 | |||||||||||||
EBITDA
|
$ | 16,066 | $ | 17,334 | $ | 43,831 | $ | 50,729 |
June
27,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
United
States
|
$ | 49,414 | $ | 51,704 | ||||
Canada
|
14,019 | 14,308 | ||||||
Other
|
54 | 36 | ||||||
$ | 63,487 | $ | 66,048 |
June
27,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
United
States
|
$ | 114,078 | $ | 113,310 | ||||
Canada
|
48,314 | 48,263 | ||||||
$ | 162,392 | $ | 161,573 |
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
June 27,
2008
|
June 29,
2007
|
June 27,
2008
|
June 29,
2007
|
|||||||||||||
United
States
|
$ | 58,131 | $ | 50,896 | $ | 174,860 | $ | 152,977 | ||||||||
All
foreign countries
|
32,603 | 36,422 | 96,588 | 106,508 | ||||||||||||
|
$ | 90,734 | $ | 87,318 | $ | 271,448 | $ | 259,485 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 193 | $ | 23,128 | $ | 859 | $ | 2,017 | $ | - | $ | 26,197 | ||||||||||||
Restricted
cash
|
- | - | 1,023 | 182 | - | 1,205 | ||||||||||||||||||
Accounts
receivable, net
|
- | 23,455 | 10,791 | 14,133 | - | 48,379 | ||||||||||||||||||
Inventories
|
- | 43,212 | 8,079 | 17,617 | (1,040 | ) | 67,868 | |||||||||||||||||
Deferred
tax assets
|
- | 9,415 | - | 608 | - | 10,023 | ||||||||||||||||||
Prepaid
and other current assets
|
- | 3,481 | 922 | 654 | - | 5,057 | ||||||||||||||||||
Intercompany
receivable
|
- | 12,715 | 5,404 | 9,240 | (27,359 | ) | - | |||||||||||||||||
Total
current assets
|
193 | 115,406 | 27,078 | 44,451 | (28,399 | ) | 158,729 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 46,248 | 3,171 | 14,068 | - | 63,487 | ||||||||||||||||||
Deferred
debt issue costs, net
|
470 | 4,892 | - | - | - | 5,362 | ||||||||||||||||||
Intangible
assets, net
|
- | 57,152 | 14,386 | 7,817 | - | 79,355 | ||||||||||||||||||
Goodwill
|
- | 92,498 | 21,631 | 48,263 | - | 162,392 | ||||||||||||||||||
Other
long-term assets
|
- | 417 | 278 | 100 | - | 795 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
180,237 | 100,320 | - | - | (280,557 | ) | - | |||||||||||||||||
Total
assets
|
$ | 180,900 | $ | 417,968 | $ | 66,544 | $ | 114,699 | $ | (309,991 | ) | $ | 470,120 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Current
portion of long-term debt
|
$ | - | $ | 2,000 | $ | - | $ | - | $ | - | $ | 2,000 | ||||||||||||
Accounts
payable
|
253 | 11,367 | 2,634 | 7,696 | - | 21,950 | ||||||||||||||||||
Accrued
expenses
|
511 | 17,683 | 3,093 | 5,086 | - | 26,373 | ||||||||||||||||||
Product
warranty
|
- | 2,154 | 503 | 1,876 | - | 4,533 | ||||||||||||||||||
Income
taxes payable
|
- | 1,904 | 164 | 5,526 | - | 7,594 | ||||||||||||||||||
Advance
payments from customers
|
- | 6,476 | 4,299 | 1,409 | - | 12,184 | ||||||||||||||||||
Intercompany
payable
|
27,359 | - | - | - | (27,359 | ) | - | |||||||||||||||||
Total
current liabilities
|
28,123 | 41,584 | 10,693 | 21,593 | (27,359 | ) | 74,634 | |||||||||||||||||
Deferred
income taxes
|
- | 21,472 | - | 5,288 | - | 26,760 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
13,892 | 214,750 | - | - | - | 228,642 | ||||||||||||||||||
Other
long-term liabilities
|
- | 1,002 | - | 197 | - | 1,199 | ||||||||||||||||||
Total
liabilities
|
42,015 | 278,808 | 10,693 | 28,113 | (28,394 | ) | 331,235 | |||||||||||||||||
Common
stock
|
165 | - | - | - | - | 165 | ||||||||||||||||||
Additional
paid-in capital
|
70,987 | - | - | - | - | 70,987 | ||||||||||||||||||
Parent
investment
|
- | 52,808 | 43,824 | 58,030 | (154,662 | ) | - | |||||||||||||||||
Accumulated
other comprehensive (loss) income
|
(997 | ) | (997 | ) | - | (89 | ) | 1,086 | (997 | ) | ||||||||||||||
Retained
earnings
|
70,530 | 87,349 | 12,027 | 28,645 | (128,021 | ) | 70,530 | |||||||||||||||||
Treasury
stock
|
(1,800 | ) | - | - | - | - | (1,800 | ) | ||||||||||||||||
Total
stockholders’ equity
|
138,885 | 139,160 | 55,851 | 86,586 | (281,597 | ) | 138,885 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 180,900 | $ | 417,968 | $ | 66,544 | $ | 114,699 | $ | (309,991 | ) | $ | 470,120 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 1,378 | $ | 16,518 | $ | 958 | $ | 1,620 | $ | - | $ | 20,474 | ||||||||||||
Restricted
cash
|
- | - | 1,945 | 310 | - | 2,255 | ||||||||||||||||||
Accounts
receivable, net
|
- | 25,857 | 10,816 | 15,916 | - | 52,589 | ||||||||||||||||||
Inventories
|
- | 43,949 | 7,092 | 17,084 | (678 | ) | 67,447 | |||||||||||||||||
Deferred
tax assets
|
- | 9,272 | 3 | 469 | - | 9,744 | ||||||||||||||||||
Intercompany
receivable
|
- | 23,312 | 2,076 | 2,736 | (28,124 | ) | - | |||||||||||||||||
Prepaid
and other current assets
|
- | 3,250 | 545 | 844 | - | 4,639 | ||||||||||||||||||
Total
current assets
|
1,378 | 122,158 | 23,435 | 38,979 | (28,802 | ) | 157,148 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 48,327 | 3,382 | 14,339 | - | 66,048 | ||||||||||||||||||
Deferred
debt issue costs, net
|
795 | 5,738 | - | - | - | 6,533 | ||||||||||||||||||
Intangible
assets, net
|
- | 67,008 | 6,465 | 8,270 | - | 81,743 | ||||||||||||||||||
Goodwill
|
- | 107,462 | 5,848 | 48,263 | - | 161,573 | ||||||||||||||||||
Other
long-term assets
|
- | 3,077 | - | 100 | - | 3,177 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
174,333 | 64,641 | - | - | (238,974 | ) | - | |||||||||||||||||
Total
assets
|
$ | 176,506 | $ | 419,446 | $ | 39,130 | $ | 109,951 | $ | (268,811 | ) | $ | 476,222 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Current
portion of long-term debt
|
$ | - | $ | 1,000 | $ | - | $ | - | $ | - | $ | 1,000 | ||||||||||||
Accounts
payable
|
224 | 10,421 | 2,430 | 8,719 | - | 21,794 | ||||||||||||||||||
Accrued
expenses
|
404 | 16,684 | 3,991 | 5,270 | - | 26,349 | ||||||||||||||||||
Product
warranty
|
- | 3,141 | 481 | 1,956 | - | 5,578 | ||||||||||||||||||
Income
taxes payable
|
- | 1,888 | 562 | 6,298 | - | 8,748 | ||||||||||||||||||
Advance
payments from customers
|
- | 5,926 | 4,933 | 1,273 | - | 12,132 | ||||||||||||||||||
Intercompany
payable
|
28,124 | - | - | - | (28,124 | ) | - | |||||||||||||||||
Total
current liabilities
|
28,752 | 39,060 | 12,397 | 23,516 | (28,124 | ) | 75,601 | |||||||||||||||||
Deferred
income taxes
|
31 | 22,833 | - | 5,530 | - | 28,394 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
21,817 | 223,750 | - | - | - | 245,567 | ||||||||||||||||||
Other
long-term liabilities
|
- | 547 | - | 207 | - | 754 | ||||||||||||||||||
Total
liabilities
|
50,600 | 286,190 | 12,397 | 30,288 | (29,159 | ) | 350,316 | |||||||||||||||||
Common
stock
|
164 | - | - | - | - | 164 | ||||||||||||||||||
Parent
investment
|
- | 60,705 | 19,167 | 57,746 | (137,618 | ) | - | |||||||||||||||||
Additional
paid-in capital
|
68,763 | - | - | - | - | 68,763 | ||||||||||||||||||
Accumulated
other comprehensive income
|
937 | 886 | - | 155 | (1,041 | ) | 937 | |||||||||||||||||
Retained
earnings
|
56,042 | 71,665 | 7,566 | 21,762 | (100,993 | ) | 56,042 | |||||||||||||||||
Total
stockholders’ equity
|
125,906 | 133,256 | 26,733 | 79,663 | (239,652 | ) | 125,906 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 176,506 | $ | 419,446 | $ | 39,130 | $ | 109,951 | $ | (268,811 | ) | $ | 476,222 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 56,694 | $ | 18,355 | $ | 34,492 | $ | (18,807 | ) | $ | 90,734 | |||||||||||
Cost
of sales
|
- | 39,343 | 15,562 | 27,127 | (18,530 | ) | 63,502 | |||||||||||||||||
Gross
profit
|
- | 17,351 | 2,793 | 7,365 | (277 | ) | 27,232 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 817 | 5 | 1,944 | - | 2,766 | ||||||||||||||||||
Selling
and marketing
|
- | 1,838 | 1,000 | 2,174 | - | 5,012 | ||||||||||||||||||
General
and administrative
|
- | 3,472 | 1,077 | 587 | - | 5,136 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 334 | 296 | 152 | - | 782 | ||||||||||||||||||
Net
loss on disposition of fixed assets
|
- | 128 | - | - | - | 128 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 6,589 | 2,378 | 4,857 | - | 13,824 | ||||||||||||||||||
Operating
income
|
- | 10,762 | 415 | 2,508 | (277 | ) | 13,408 | |||||||||||||||||
Interest
expense (income), net
|
357 | 4,266 | (10 | ) | 14 | - | 4,627 | |||||||||||||||||
Loss
on debt extinguishment
|
121 | - | - | - | - | 121 | ||||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(478 | ) | 6,496 | 425 | 2,494 | (277 | ) | 8,660 | ||||||||||||||||
Income
tax (benefit) expense
|
(181 | ) | 2,592 | 106 | 319 | - | 2,836 | |||||||||||||||||
Equity
in income of subsidiaries
|
6,121 | 2,217 | - | - | (8,338 | ) | - | |||||||||||||||||
Net
income
|
$ | 5,824 | $ | 6,121 | $ | 319 | $ | 2,175 | $ | (8,615 | ) | $ | 5,824 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 55,453 | $ | 15,073 | $ | 37,186 | $ | (20,394 | ) | $ | 87,318 | |||||||||||
Cost
of sales
|
- | 38,210 | 12,660 | 28,182 | (20,385 | ) | 58,667 | |||||||||||||||||
Gross
profit
|
- | 17,243 | 2,413 | 9,004 | (9 | ) | 28,651 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 716 | - | 1,516 | - | 2,232 | ||||||||||||||||||
Selling
and marketing
|
- | 2,019 | 924 | 1,968 | - | 4,911 | ||||||||||||||||||
General
and administrative
|
- | 3,453 | 246 | 2,136 | - | 5,835 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 334 | 62 | 152 | - | 548 | ||||||||||||||||||
Net
loss on disposition of fixed assets
|
- | 1 | - | 15 | - | 16 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 6,523 | 1,232 | 5,787 | - | 13,542 | ||||||||||||||||||
Operating
income
|
- | 10,720 | 1,181 | 3,217 | (9 | ) | 15,109 | |||||||||||||||||
Interest
expense (income), net
|
1,950 | 3,198 | (15 | ) | 10 | - | 5,143 | |||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(1,950 | ) | 7,522 | 1,196 | 3,207 | (9 | ) | 9,966 | ||||||||||||||||
Income
tax (benefit) expense
|
(765 | ) | 1,448 | 321 | 831 | - | 1,835 | |||||||||||||||||
Equity
in income of subsidiaries
|
9,316 | 3,242 | - | - | (12,558 | ) | - | |||||||||||||||||
Net
income
|
$ | 8,131 | $ | 9,316 | $ | 875 | $ | 2,376 | $ | (12,567 | ) | $ | 8,131 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 166,793 | $ | 59,306 | $ | 103,820 | $ | (58,471 | ) | $ | 271,448 | |||||||||||
Cost
of sales
|
- | 119,652 | 50,038 | 80,433 | (58,109 | ) | 192,014 | |||||||||||||||||
Gross
profit
|
- | 47,141 | 9,268 | 23,387 | (362 | ) | 79,434 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 2,438 | 426 | 5,556 | - | 8,420 | ||||||||||||||||||
Selling
and marketing
|
- | 5,831 | 3,187 | 6,494 | - | 15,512 | ||||||||||||||||||
General
and administrative
|
- | 11,007 | 3,165 | 2,609 | - | 16,781 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 1,002 | 889 | 453 | - | 2,344 | ||||||||||||||||||
Net
loss on disposition of fixed assets
|
- | 172 | 12 | 19 | - | 203 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 20,450 | 7,679 | 15,131 | - | 43,260 | ||||||||||||||||||
Operating
income
|
- | 26,691 | 1,589 | 8,256 | (362 | ) | 36,174 | |||||||||||||||||
Interest
expense (income), net
|
1,414 | 12,865 | (47 | ) | 12 | - | 14,244 | |||||||||||||||||
Loss
on debt extinguishment
|
514 | - | - | - | - | 514 | ||||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(1,928 | ) | 13,826 | 1,636 | 8,244 | (362 | ) | 21,416 | ||||||||||||||||
Income
tax (benefit) expense
|
(732 | ) | 6,074 | 225 | 1,361 | - | 6,928 | |||||||||||||||||
Equity
in income of subsidiaries
|
15,684 | 7,932 | - | - | (23,616 | ) | - | |||||||||||||||||
Net
income
|
$ | 14,488 | $ | 15,684 | $ | 1,411 | $ | 6,883 | $ | (23,978 | ) | $ | 14,488 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 163,484 | $ | 46,004 | $ | 105,872 | $ | (55,875 | ) | $ | 259,485 | |||||||||||
Cost
of sales
|
- | 113,916 | 38,367 | 80,863 | (56,598 | ) | 176,548 | |||||||||||||||||
Gross
profit
|
- | 49,568 | 7,637 | 25,009 | 723 | 82,937 | ||||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 2,261 | - | 4,214 | - | 6,475 | ||||||||||||||||||
Selling
and marketing
|
- | 6,003 | 2,622 | 5,914 | - | 14,539 | ||||||||||||||||||
General
and administrative
|
- | 11,546 | 968 | 3,571 | - | 16,085 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 1,002 | 187 | 453 | - | 1,642 | ||||||||||||||||||
Net
loss on disposition of fixed assets
|
- | 18 | - | 56 | - | 74 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 20,830 | 3,777 | 14,208 | - | 38,815 | ||||||||||||||||||
Operating
income
|
- | 28,738 | 3,860 | 10,801 | 723 | 44,122 | ||||||||||||||||||
Interest
expense (income), net
|
6,070 | 9,817 | (30 | ) | (100 | ) | - | 15,757 | ||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(6,070 | ) | 18,921 | 3,890 | 10,901 | 723 | 28,365 | |||||||||||||||||
Income
tax (benefit) expense
|
(2,331 | ) | 6,669 | 1,058 | 3,243 | - | 8,639 | |||||||||||||||||
Equity
in income of subsidiaries
|
23,465 | 11,213 | - | - | (34,678 | ) | - | |||||||||||||||||
Net
income
|
$ | 19,726 | $ | 23,465 | $ | 2,832 | $ | 7,658 | $ | (33,955 | ) | $ | 19,726 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net cash (used in) provided by operating activities
|
$ | (2,127 | ) | $ | 25,560 | $ | 271 | $ | 995 | $ | - | $ | 24,699 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (2,467 | ) | (223 | ) | (598 | ) | - | (3,288 | ) | ||||||||||||||
Proceeds
from adjustment to acquisition purchase price
|
- | 1,615 | - | - | - | 1,615 | ||||||||||||||||||
Payment
of patent application fees
|
- | - | (147 | ) | - | - | (147 | ) | ||||||||||||||||
Net
cash used in investing activities
|
- | (852 | ) | (370 | ) | (598 | ) | - | (1,820 | ) | ||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Purchases
of treasury stock
|
(1,800 | ) | - | - | - | - | (1,800 | ) | ||||||||||||||||
Repayments
of debt
|
(8,000 | ) | (8,000 | ) | - | - | - | (16,000 | ) | |||||||||||||||
Proceeds
from issuance of common stock to employees
|
639 | - | - | - | - | 639 | ||||||||||||||||||
Proceeds
from exercise of stock options
|
3 | - | - | - | - | 3 | ||||||||||||||||||
Excess
tax benefit on stock option exercises
|
- | 2 | - | - | - | 2 | ||||||||||||||||||
Intercompany
dividends
|
10,100 | (10,100 | ) | - | - | - | - | |||||||||||||||||
Net
cash provided by (used in) financing activities
|
942 | (18,098 | ) | - | - | - | (17,156 | ) | ||||||||||||||||
Net
(decrease) increase in cash and cash equivalents
|
(1,185 | ) | 6,610 | (99 | ) | 397 | - | 5,723 | ||||||||||||||||
Cash
and cash equivalents at beginning of period
|
1,378 | 16,518 | 958 | 1,620 | - | 20,474 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 193 | $ | 23,128 | $ | 859 | $ | 2,017 | $ | - | $ | 26,197 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net cash (used in) provided by operating activities
|
$ | (619 | ) | $ | 14,898 | $ | 872 | $ | 4,108 | $ | - | $ | 19,259 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (2,423 | ) | (24 | ) | (3,945 | ) | - | (6,392 | ) | ||||||||||||||
Capitalized
expenses relating to potential business acquisition
|
- | (395 | ) | - | - | - | (395 | ) | ||||||||||||||||
Net
cash used in investing activities
|
- | (2,818 | ) | (24 | ) | (3,945 | ) | - | (6,787 | ) | ||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Repayments
of debt
|
- | (5,000 | ) | - | - | - | (5,000 | ) | ||||||||||||||||
Proceeds
from issuance of common stock to employees
|
520 | - | - | - | - | 520 | ||||||||||||||||||
Proceeds
from exercise of stock options
|
604 | - | - | - | - | 604 | ||||||||||||||||||
Excess
tax benefit on stock option exercises
|
- | 671 | - | - | - | 671 | ||||||||||||||||||
Intercompany
dividends
|
2,800 | (2,800 | ) | - | - | - | - | |||||||||||||||||
Net
cash provided by (used in) financing activities
|
3,924 | (7,129 | ) | - | - | - | (3,205 | ) | ||||||||||||||||
Net
increase in cash and cash equivalents
|
3,305 | 4,951 | 848 | 163 | - | 9,267 | ||||||||||||||||||
Cash
and cash equivalents at beginning of period
|
139 | 28,299 | 290 | 1,425 | - | 30,153 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 3,444 | $ | 33,250 | $ | 1,138 | $ | 1,588 | $ | - | $ | 39,420 |
Nine
Months Ended
|
||||||||||||||||||||||||
June
27, 2008
|
June
29, 2007
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Orders
|
Amount
|
Orders
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 109.3 | 39 | % | $ | 109.4 | 40 | % | $ | (0.1 | ) | (0 | ) % | |||||||||||
Medical
|
48.3 | 17 | 53.9 | 20 | (5.6 | ) | (10 | ) | ||||||||||||||||
Communications
|
92.8 | 33 | 81.7 | 31 | 11.1 | 14 | ||||||||||||||||||
Industrial
|
19.8 | 8 | 16.1 | 6 | 3.7 | 23 | ||||||||||||||||||
Scientific
|
9.7 | 3 | 8.3 | 3 | 1.4 | 17 | ||||||||||||||||||
|
$ | 279.9 | 100 | % | $ | 269.4 | 100 | % | $ | 10.5 | 4 | % |
|
·
|
Radar and Electronic
Warfare: The majority of our sales in the radar and electronic
warfare markets are for products for domestic and international defense
and government end uses. Orders in these markets are characterized by many
smaller orders in the $0.5 million to $3.0 million range by product or
program, and the timing of these orders may vary from year to year. On a
combined basis, orders for the radar and electronic warfare markets for
the nine months ended June 29, 2007 and the nine months ended June 27,
2008 were approximately equal, totaling an aggregate of $109.4 million and
$109.3 million, respectively. In the nine months ended June 27, 2008,
radar orders received by our recently acquired Malibu division and
increased demand for radar products to support the HAWK missile system
were partially offset by decreased demand for radar products to support
the Aegis weapons system, continued delays in the placement of defense
orders and an expected decrease in orders to support the EarthCARE
cloud-profiling radar program due to the timing of that
program.
Demand
for our products to support ships with the Aegis weapons system has two
components: we support new ship builds and we provide spare and repair
products for previously fielded ships. Over the past several years, we
have seen high demand for products to support a significant number of new
ship builds for the Aegis weapons program for U.S. and international
military customers. We have now received all orders for our products
required to support these new ship builds. As a result, we expect the
near-term demand to be primarily for spare and repair products and,
therefore, at overall lower levels than in the past several years. We
expect demand for our products to increase again as the new ships are
commissioned, deployed and added to the installed base, after which they
will require spare and repair products.
During
fiscal year 2008, delays in the receipt of orders for radar and electronic
warfare programs have subsequently impacted the timing of our sales for
these programs. We expect these delays to continue for the
foreseeable future.
|
|
·
|
Medical: Orders for
our medical products consist of orders for medical imaging applications,
such as x-ray imaging, positron emission tomography (“PET”) and magnetic
resonance imaging (“MRI”), and for radiation therapy applications for the
treatment of cancer. The 10% decrease in medical orders was attributable
to the timing of a Russian tender program and orders for MRI products, and
was partially offset by an increase in orders for x-ray generators from
one large customer and other international customers, as well as an
increase in orders for products for radiation therapy
applications.
A Russian tender program in which we
participated in fiscal years 2006 and 2007 will not recur in fiscal year
2008. In the nine months ended June 29, 2007, we received approximately
$5.0 million of the fiscal year’s $5.8 million in orders for the Russian
tender program; we received no such orders in the nine months ended June
27, 2008.
|
In
addition, in fiscal year 2007, demand for products for MRI applications
was very strong, as a large customer ordered a two-year supply of these
products in one fiscal year, and we shipped a significant amount of these
products during that fiscal year. As a result, in the nine months ended
June 27, 2008, orders for products for MRI applications decreased
approximately $6.7 million as compared to the corresponding period of
fiscal year 2007.
|
|
·
|
Communications: The
14% increase in communications orders was primarily attributable to
telemetry orders received by our recently acquired Malibu division, as
well as the receipt of our first production orders, totaling approximately
$12 million, for Increment One of the Warfighter Information Network
Tactical (“WIN-T”) military communications program. These increases were
partially offset by a decrease in orders for certain military
communications programs, including WIN-T’s predecessor program, the
now-completed Joint Network Node (“JNN”) military
communications program, for which we had strong demand in the nine
months ended June 29, 2007, and a decrease in orders for
direct-to-home broadcast applications due to order timing.
In the nine months ended June 27, 2008, as
the WIN-T program began to ramp up for production, orders to support the
predecessor JNN program decreased $4.3 million due to the completion of
that program. Once the WIN-T program is fully ramped up for
production, we expect that our overall participation levels in the WIN-T
program will be significantly higher than our participation levels in the
previous JNN program.
|
|
·
|
Industrial: Orders in
the industrial market are cyclical. The $3.7 million increase in
industrial orders was attributable to orders for products used in a wide
variety of industrial applications, including industrial fabrication
applications, international test systems and food processing, cargo
screening and other industrial
applications.
|
|
·
|
Scientific: Orders in
the scientific market are historically one-time projects and can fluctuate
significantly from period to period. The $1.4 million increase in
scientific orders was primarily the result of orders for products to
support a new accelerator project for fusion research at an international
scientific institute.
|
Three
Months Ended
|
||||||||||||||||||||
June
27, 2008
|
June
29, 2007
|
Increase
(Decrease)
|
||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
||||||||||||||||
Sales
|
$ | 90.7 | 100.0 | % | $ | 87.3 | 100.0 | % | $ | 3.4 | ||||||||||
Cost
of sales
|
63.5 | 70.0 | 58.7 | 67.2 | 4.8 | |||||||||||||||
Gross
profit
|
27.2 | 30.0 | 28.7 | 32.9 | (1.5 | ) | ||||||||||||||
Research
and development
|
2.8 | 3.1 | 2.2 | 2.5 | 0.6 | |||||||||||||||
Selling
and marketing
|
5.0 | 5.5 | 4.9 | 5.6 | 0.1 | |||||||||||||||
General
and administrative
|
5.1 | 5.6 | 5.8 | 6.6 | (0.7 | ) | ||||||||||||||
Amortization
of acquisition-related intangibles
|
0.8 | 0.9 | 0.5 | 0.6 | 0.3 | |||||||||||||||
Net
loss on disposition of assets
|
0.1 | 0 | - | - | 0.1 | |||||||||||||||
Operating
income
|
13.4 | 14.8 | 15.1 | 17.3 | (1.7 | ) | ||||||||||||||
Interest
expense, net
|
4.6 | 5.1 | 5.1 | 5.8 | (0.5 | ) | ||||||||||||||
Loss
on debt extinguishment
|
0.1 | 0.1 | - | - | 0.1 | |||||||||||||||
Income
before taxes
|
8.7 | 9.6 | 10.0 | 11.5 | (1.3 | ) | ||||||||||||||
Income
tax expense
|
2.8 | 3.1 | 1.8 | 2.1 | 1.0 | |||||||||||||||
Net
income
|
$ | 5.8 | 6.4 | % | $ | 8.1 | 9.3 | % | $ | (2.3 | ) | |||||||||
Other
Data:
|
||||||||||||||||||||
EBITDA
(a)
|
$ | 16.1 | 17.8 | % | $ | 17.3 | 19.8 | % | $ | (1.2 | ) |
|
Note: Totals
may not equal the sum of the component line items due to independent
rounding. Percentages are calculated based on rounded dollar amounts
presented.
|
|
(a)
|
EBITDA
represents earnings before net interest expense, provision for income
taxes and depreciation and amortization. For the reasons listed below, we
believe that GAAP-based financial information for leveraged businesses
such as ours should be supplemented by EBITDA so that investors better
understand our financial performance in connection with their analysis of
our business:
|
|
•
|
EBITDA
is a component of the measures used by our board of directors and
management team to evaluate our operating
performance;
|
|
•
|
our
senior credit facilities contain a covenant that requires us to maintain a
senior secured leverage ratio that contains EBITDA as a component, and our
management team uses EBITDA to monitor compliance with such
covenant;
|
|
•
|
EBITDA
is a component of the measures used by our management team to make
day-to-day operating decisions;
|
|
•
|
EBITDA
facilitates comparisons between our operating results and those of
competitors with different capital structures and therefore is a component
of the measures used by the management to facilitate internal comparisons
to competitors' results and our industry in general;
and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by us of certain targets that contain EBITDA as a
component.
|
|
Other
companies may define EBITDA differently and, as a result, our measure of
EBITDA may not be directly comparable to EBITDA of other companies.
Although we use EBITDA as a financial measure to assess the performance of
our business, the use of EBITDA is limited because it does not include
certain material costs, such as interest and taxes, necessary to operate
our business. When analyzing our performance, EBITDA should be considered
in addition to, and not as a substitute for, net income, cash flows from
operating activities or other statements of operations or statements of
cash flows data prepared in accordance with
GAAP.
|
Three
Months Ended
|
||||||||||||||||||||||||
June
27, 2008
|
June
29, 2007
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 38.2 | 42 | % | $ | 36.5 | 42 | % | $ | 1.7 | 5 | % | ||||||||||||
Medical
|
16.8 | 19 | 18.0 | 21 | (1.2 | ) | (7 | ) | ||||||||||||||||
Communications
|
28.0 | 31 | 27.3 | 31 | 0.7 | 3 | ||||||||||||||||||
Industrial
|
5.8 | 6 | 4.7 | 5 | 1.1 | 23 | ||||||||||||||||||
Scientific
|
1.9 | 2 | 0.8 | 1 | 1.1 | 138 | ||||||||||||||||||
|
$ | 90.7 | 100 | % | $ | 87.3 | 100 | % | $ | 3.4 | 4 | % |
|
·
|
Radar and Electronic
Warfare: The majority of our sales in the radar and electronic
warfare markets are for products for domestic and international defense
and government end uses. The timing of orders receipts and
subsequent shipments in these markets may vary from year to
year. On a combined basis, sales for these two markets
increased approximately 5% from $36.5 million in the three months ended
June 29, 2007 to $38.2 million in the three months ended June 27, 2008,
primarily due to increased sales of products to support military radar
systems, including the HAWK missile system, as well as sales of radar
products by our recently acquired Malibu
division.
|
|
·
|
Medical: Sales of our medical products consist of sales for medical imaging applications, such as x-ray imaging, PET and MRI, and for radiation therapy applications for the treatment of cancer. Sales levels in this market decreased 7%, primarily due to a Russian tender program in which we participated in fiscal years 2006 and 2007 that will not recur in fiscal year 2008. In the three months ended June 29, 2007, we shipped $2.9 million of x-ray generators for this program; we made no such shipments in the three months ended June 27, 2008. These sales decreases were partially offset by an increase in sales of x-ray generators to one large customer and other international customers, as well as an increase in sales of products for radiation therapy applications. |
|
·
|
Communications: The
3% increase in sales in the communications market was primarily the result
of sales of telemetry products by our recently acquired Malibu division,
as well as the recently begun production shipments for Increment One of
the WIN-T military communications program. These increases were partially
offset by a decrease in sales of products for another military
communications program and certain broadcast applications.
In the three months ended June 27, 2008, we
shipped $2.3 million in products to support the WIN-T military
communications program as it began to ramp up for production. These sales
were partially offset by an approximately $1 million decrease in
sales of products to support its predecessor, the JNN military
communications program, due to the completion of that program. We expect
that our overall participation levels in the WIN-T program will be
significantly higher than our participation levels in the previous JNN
program.
|
|
·
|
Industrial: Sales in the
industrial market are cyclical. The $1.1 million increase in industrial
sales was due to sales of products used in a wide variety of industrial
applications, including industrial fabrication applications and domestic
and international test systems.
|
|
·
|
Scientific: Sales
in the scientific market are historically one-time projects and can
fluctuate significantly from period to period. The $1.1 million increase
in scientific sales was primarily the result of increased product
shipments for the Spallation Neutron Source at Oakridge National
Laboratory. We received approximately $5 million in orders for this
program in fiscal year 2007 and expect to complete our shipments of
products for this program in the second quarter of fiscal year
2009.
|
Three Months Ended
|
||||||||
June
27,
|
June
29,
|
|||||||
2008
|
2007
|
|||||||
Company
funded costs
|
$ | 2.8 | $ | 2.2 | ||||
Customer
funded costs, charged to cost of sales
|
2.2 | 1.7 | ||||||
$ | 5.0 | $ | 3.9 |
Nine
Months Ended
|
||||||||||||||||||||
June
27, 2008
|
June
29, 2007
|
Increase
(Decrease)
|
||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
||||||||||||||||
Sales
|
$ | 271.4 | 100.0 | % | $ | 259.5 | 100.0 | % | $ | 11.9 | ||||||||||
Cost
of sales
|
192.0 | 70.7 | 176.5 | 68.0 | 15.5 | |||||||||||||||
Gross
profit
|
79.4 | 29.3 | 82.9 | 31.9 | (3.5 | ) | ||||||||||||||
Research
and development
|
8.4 | 3.1 | 6.5 | 2.5 | 1.9 | |||||||||||||||
Selling
and marketing
|
15.5 | 5.7 | 14.5 | 5.6 | 1.0 | |||||||||||||||
General
and administrative
|
16.8 | 6.2 | 16.1 | 6.2 | 0.7 | |||||||||||||||
Amortization
of acquisition-
|
||||||||||||||||||||
related
intangibles
|
2.3 | 0.8 | 1.6 | 0.6 | 0.7 | |||||||||||||||
Net
loss on disposition of assets
|
0.2 | 0.1 | 0.1 | 0.0 | 0.1 | |||||||||||||||
Operating
income
|
36.2 | 13.3 | 44.1 | 17.0 | (7.9 | ) | ||||||||||||||
Interest
expense, net
|
14.2 | 5.2 | 15.8 | 6.1 | (1.6 | ) | ||||||||||||||
Loss
on debt extinguishment
|
0.5 | 0.2 | - | - | 0.5 | |||||||||||||||
Income
before taxes
|
21.4 | 7.9 | 28.4 | 10.9 | (7.0 | ) | ||||||||||||||
Income
tax expense
|
6.9 | 2.5 | 8.6 | 3.3 | (1.7 | ) | ||||||||||||||
Net
income
|
$ | 14.5 | 5.3 | % | $ | 19.7 | 7.6 | % | $ | (5.2 | ) | |||||||||
Other
Data:
|
||||||||||||||||||||
EBITDA
(a)
|
$ | 43.8 | 16.1 | % | $ | 50.7 | 19.5 | % | $ | (6.9 | ) |
|
Note: Totals
may not equal the sum of the component line items due to independent
rounding. Percentages are calculated based on rounded dollar amounts
presented.
|
|
(a) |
EBITDA
represents earnings before net interest expense, provision for income
taxes and depreciation and amortization. For the reasons listed below, we
believe that GAAP-based financial information for leveraged businesses
such as ours should be supplemented by EBITDA so that investors
better understand our financial performance in connection with their
analysis of our business:
|
|
•
|
EBITDA
is a component of the measures used by our board of directors and
management team to evaluate our operating
performance;
|
|
•
|
our
senior credit facilities contain a covenant that requires us to maintain a
senior secured leverage ratio that contains EBITDA as a component, and our
management team uses EBITDA to monitor compliance with such
covenant;
|
|
•
|
EBITDA
is a component of the measures used by our management team to make
day-to-day operating decisions;
|
|
•
|
EBITDA
facilitates comparisons between our operating results and those of
competitors with different capital structures and therefore is a component
of the measures used by the management to facilitate internal comparisons
to competitors' results and our industry in general;
and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by us of certain targets that contain EBITDA as a
component.
|
|
Other
companies may define EBITDA differently and, as a result, our measure of
EBITDA may not be directly comparable to EBITDA of other companies.
Although we use EBITDA as a financial measure to assess the performance of
our business, the use of EBITDA is limited because it does not include
certain material costs, such as interest and taxes, necessary to operate
our business. When analyzing our performance, EBITDA should be considered
in addition to, and not as a substitute for, net income, cash flows from
operating activities or other statements of operations or statements of
cash flows data prepared in accordance with
GAAP.
|
Nine
Months Ended
|
||||||||||||||||||||||||
June
27, 2008
|
June
29, 2007
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 114.1 | 42 | % | $ | 106.7 | 41 | % | $ | 7.4 | 7 | % | ||||||||||||
Medical
|
49.5 | 18 | 52.1 | 20 | (2.6 | ) | (5 | ) | ||||||||||||||||
Communications
|
82.5 | 30 | 80.5 | 31 | 2.0 | 2 | ||||||||||||||||||
Industrial
|
17.9 | 7 | 16.1 | 6 | 1.8 | 11 | ||||||||||||||||||
Scientific
|
7.4 | 3 | 4.1 | 2 | 3.3 | 80 | ||||||||||||||||||
|
$ | 271.4 | 100 | % | $ | 259.5 | 100 | % | $ | 11.9 | 5 | % |
|
·
|
Radar and Electronic
Warfare: The majority of our sales in the radar and electronic
warfare markets are for products for domestic and international defense
and government end uses. The timing of orders receipts and subsequent
shipments in these markets may vary from year to year. On a
combined basis, sales for these two markets increased approximately 7%
from $106.7 million in the nine months ended June 29, 2007 to $114.1
million in the corresponding period of fiscal year 2008. The increase in
sales was due primarily to sales of radar products by our recently
acquired Malibu division and increased sales to support the HAWK missile
system and other radar systems.
|
|
·
|
Medical: Sales of our
medical products consist of sales for medical imaging applications, such
as x-ray imaging, PET and MRI, and for radiation therapy applications for
the treatment of cancer. The 5% decrease in sales of our medical products
was primarily due to a Russian tender program in which we participated in
fiscal years 2006 and 2007 that will not recur in fiscal year 2008. In the
nine months ended June 29, 2007, we shipped approximately $3.7 million of
the fiscal year’s $5.9 million in sales for the Russian tender program; we
made no such sales in the nine months ended June 27, 2008.
In
addition, in fiscal year 2007, a large customer ordered a two-year supply
of products for MRI applications in one fiscal year, resulting in
unusually strong demand for these products, and we shipped a significant
amount of these products during that fiscal year. As a result, in the nine
months ended June 27, 2008, sales of products for MRI applications were
solid but decreased approximately $1.6 million.
We
are seeing some softening in demand for x-ray generators for U.S.
customers due the impact of the phasing in of the Deficit Reduction Act of
2005 and currently challenging
credit
|
conditions. Sales
of x-ray generators for U.S. customers in the nine months ended June 27,
2008 were $0.8 million lower than in nine months ended June 29,
2007.
These
decreases were partially offset by an increase in sales of x-ray
generators for one large customer and other international
customers.
|
|
·
|
Communications: The
2% increase in sales in the communications market was primarily the result
of sales of telemetry products by our recently acquired Malibu division,
as well as the start of our first production shipments for Increment One
of the WIN-T military communications program. These increases were
partially offset by a decrease in sales of products for certain military
communications programs, including the now-completed JNN program, and
certain broadcast network applications for which we had strong sales in
the first nine months of fiscal year 2007.
In the nine months ended June 27, 2008, the
$3.9 million increase in sales of products to support the WIN-T military
communications program as it began to ramp up for production was offset by
a $3.4 million decrease in sales of products to support its predecessor,
the JNN military communications program, due to the completion of that
program. We expect that our overall participation levels in the WIN-T
program will be significantly higher than our participation levels in the
previous JNN program.
|
|
·
|
Industrial: Sales in the
industrial market are cyclical. The $1.8 million increase in
industrial sales was due to sales of products used in a wide variety of
industrial applications, including industrial fabrication applications and
domestic and international test
systems.
|
|
·
|
Scientific: Sales
in the scientific market are historically one-time projects and can
fluctuate significantly from period to period. The $3.3 million increase
in scientific sales was primarily the result of increased product
shipments for the Spallation Neutron Source at Oakridge National
Laboratory. We received approximately $5 million in orders for this
program in fiscal year 2007 and expect to complete our shipments of
products for this program in the second quarter of fiscal year
2009.
|
Nine Months Ended
|
||||||||
June
27,
|
June
29,
|
|||||||
2008
|
2007
|
|||||||
Company
funded costs
|
$ | 8.4 | $ | 6.5 | ||||
Customer
funded costs, charged to cost of sales
|
$ | 9.5 | $ | 5.0 | ||||
$ | 17.9 | $ | 11.5 |
June
27,
2008
|
September
28,
2007
|
|||||||
Cash
and cash equivalents
|
$ | 26,197 | $ | 20,474 | ||||
Working
capital
|
84,095 | 81,547 |
Period
|
Total
Number of Shares Purchased
|
Average Price Paid per
Share1
|
Total
Number of Shares Purchased as Part of Publicly Announced Plans or
Programs
|
Approximate
Dollar Value of Shares that May Yet Be Purchased Under the Plans or
Programs
(in thousands)2
|
|||||||||||||
March
29-April 25, 2008
|
- | $ | - | - | - | ||||||||||||
April
26-May 23, 2008
|
- | $ | - | - | - | ||||||||||||
May
24-June 27, 2008
|
136,215 | $ | 13.17 | 136,215 | $ | 10,200 | |||||||||||
136,215 | $ | 13.17 | 136,215 | $ | 10,200 | ||||||||||||
1
Excludes brokerage commission of $0.04 per share.
|
|||||||||||||||||
2 On
May 28, 2008, the Company announced the approval of its common stock
repurchase program, which authorizes the Company to repurchase up to $12.0
million of its common stock from time to time. The program may be modified
or terminated by the Company’s board of directors at any
time.
|
No.
|
Description
|
|
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
|
31.2
|
Certification
of Chief Financial Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
|
32.1
|
Certifications
of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
32.2
|
Certifications
of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
Dated:
August 6, 2008
|
/s/ JOEL A. LITTMAN
|
Joel
A. Littman
Chief
Financial Officer, Treasurer and Secretary
(Duly
Authorized Officer and Chief Financial
Officer)
|